by Metabolism Drugs helps regulate and balance the important chemical reactions in the body. These drugs help control blood sugar levels, cholesterol levels, improve digestion, and assist in weight management.
The global Metabolism Drugs Market is estimated to be valued at US$ 8169.16 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of lifestyle diseases like diabetes and obesity has boosted the Metabolism Drugs Market. As per estimates, more than 460 million people worldwide have diabetes. Also, globally over 650 million adults are obese. Lifestyle diseases are caused mainly due to changing dietary patterns and lack of physical activity. Metabolism Drugs help metabolize food properly and aid weight management which is driving their demand. These drugs assist patients in regulating their blood sugar and cholesterol levels. Hence, the growing burden of lifestyle diseases will augment the growth of this market over the forecast period.
SWOT Analysis
Strength: Metabolism drugs help regulate and treat metabolic disorders and conditions effectively. They help improve overall health and quality of life for patients.
Weakness: High costs associated with development and clinical trials of new metabolism drugs. Adverse side effects of certain metabolism medications on some patients.
Opportunity: Growing prevalence of metabolic disorders globally due to changing lifestyles and diets presents major market opportunities. Scope for development of innovative drug delivery systems.
Threats: Intense competition among existing key players. Potential regulation changes affecting drug approval procedures.
Key Takeaways
The Global Metabolism Drugs Market Size is expected to witness high growth. The market size for 2024 is projected to reach US$ 8169.16 Mn, registering a CAGR of 7.6% during the forecast period of 2023 to 2030.
Regional analysis: North America dominates the global market currently due to higher healthcare spending and more awareness about metabolic disorders. However, Asia Pacific is expected to grow at the fastest pace owing to rising income levels, growing obesity, and increasing health consciousness in major countries like China and India.
Key players: Central Admixture Pharmacy Services, Inc., Nephron Pharmaceuticals Corporation, QuVa Pharma, Olympia Pharmacy, ASP Cares, Fagron Compounding Pharmacies, Athenex, Inc., Avella Specialty Pharmacy, Atlas Pharmaceuticals, Empower Pharmacy, Carie Boyd€TMS Prescription Shop, Edge Pharma, Imprimis NJOF, LLC, IntegraDose Compounding services, LLC, Wells Pharma of Houston, LLC, US Compounding Inc., and SCA Pharma are some of the key players operating in the Metabolism Drugs market. The major players are focusing on new product launches, licensing agreements and partnerships to expand their business and maintain their leading position in the global market.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemicals and materials, defense and aerospace, consumer goods, etc.
